NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Stride, Inc. (NYSE: LRN) and certain of the Company’s senior executives for securities fraud after significant stock drops resulting from the potential violations of the federal securities laws. If you invested in Stride, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/stride-inc-class-actio ...

Core Viewpoint - Firefly Aerospace Inc. is facing a class action lawsuit due to alleged violations of securities laws related to its IPO and subsequent financial disclosures, which reportedly misrepresented the company's operational readiness and financial performance [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Diamond v. Firefly Aerospace Inc. and involves claims against the company and its executives for misleading statements made during the IPO and throughout the class period from August 7, 2025, to September 29, 2025 [1][3]. - The lawsuit alleges that Firefly Aerospace overstated demand for its Spacecraft Solutions and the viability of its Alpha rocket program, which could have a significant negative impact on the company once revealed [3][4]. Group 2: Financial Performance - Firefly Aerospace reported a loss of $80.3 million for Q2 2025, an increase from a loss of $58.7 million in Q2 2024, and revenue of $15.55 million, which was below analyst expectations of $17.25 million and a 26.2% decrease from the previous year [4]. - The company's Spacecraft Solutions segment reported revenue of only $9.2 million, reflecting a 49% year-over-year decline, contributing to a significant drop in share price of over 15% following the earnings report [4]. Group 3: Subsequent Developments - On September 29, 2025, Firefly Aerospace disclosed an incident involving the loss of the first stage of its Alpha Flight 7 rocket, which led to a further decline in share price of more than 20% [5].

Core Viewpoint - Kirby McInerney LLP is investigating potential claims against Nutanix, Inc. regarding possible violations of federal securities laws or unlawful business practices by the Company or its senior management [1] Group 1 - Nutanix published its first quarter fiscal 2026 revenue results on November 25, 2025, after the market closed [1]

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Inovio and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On Dece ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Village Farms International, Inc. and its officers or directors [1]. Group 1: Company Developments - On December 2, 2025, Village Farms announced it did not receive a conditional medical license from the Texas Department of Public Safety, which was part of the Phase I license awards [3]. - Following this announcement, Village Farms' stock price decreased by $0.37 per share, representing a 9.3% decline, closing at $3.61 per share on the same day [3]. Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of Village Farms to discuss claims related to potential securities fraud [1]. - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Ventyx Biosciences, Inc. and its officers or directors [1] Group 1: Company Developments - On December 2, 2025, Ventyx announced a revision of its guidance for the topline data release from the interim analysis of its Phase 2 study of VTX2735, now expected in Q1 2026 [3] - The CEO indicated that this shift allows for the introduction of dose-ranging studies with a new once-daily formulation and expansion into Canada, the EU, and the UK, which is believed to accelerate Phase 3 timelines [3] - Following this announcement, Ventyx's stock price decreased by $1.44 per share, or 15.35%, closing at $7.94 per share on the same day [3] Group 2: Legal Investigation - Pomerantz LLP is actively seeking claims from investors of Ventyx regarding potential securities fraud [1] - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [5][4]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to between $1.840 billion and $1.854 billion, a decrease from the previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations. The company also projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6]. Legal Proceedings - Investors have until February 9, 2026, to request to lead the case in the U.S. District Court for the Southern District of New York, under the case caption West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al. [3]. Legal Representation - Bleichmar Fonti & Auld LLP, a leading international law firm, is representing the plaintiffs in this class action lawsuit, having a strong track record in securities class actions and shareholder litigation [8].

New York, New York--(Newsfile Corp. - December 30, 2025) - Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against CarMax, Inc. (NYSE: KMX) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in CarMax, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/carma ...

Core Viewpoint - The Portnoy Law Firm has initiated an investigation into Ultragenyx Pharmaceutical, Inc. for possible securities fraud following the failure of its clinical trials, which has led to a significant drop in the company's stock price [1][3]. Group 1: Company Performance - On December 29, 2025, Ultragenyx announced that its Phase III Orbit and Cosmic studies for setrusumab (UX143) did not meet their primary endpoint of reducing annualized clinical fracture rates compared to placebo and biophosphonates [3]. - Although the studies showed improvements in secondary endpoints related to bone material density, these did not correlate with a statistically significant reduction in fractures [3]. - Following the announcement, Ultragenyx's stock price fell by $14.87 (43.49%) to open at $19.32 per share, marking a new 52-week low, significantly below the previous low of $25.81 [3]. Group 2: Legal Actions - The Portnoy Law Firm is representing investors in pursuing claims related to corporate wrongdoing, and has a history of recovering over $5.5 billion for aggrieved investors [3]. - Investors are encouraged to contact the firm for a complimentary case evaluation and to discuss their legal rights regarding potential claims [2].

Core Viewpoint - Klarna Group plc is facing a class action lawsuit related to its September 10, 2025 IPO, alleging that the offering documents were misleading regarding the company's financial risks and loss reserves [1][3]. Group 1: Class Action Lawsuit Details - The class action lawsuit, titled Nayak v. Klarna Group plc, allows investors who purchased Klarna securities during the IPO to seek appointment as lead plaintiff by February 20, 2026 [1][5]. - Klarna's IPO involved the issuance of approximately 34 million shares at an offering price of $40.00 per share [2]. - The lawsuit claims that Klarna understated the risk of increased loss reserves shortly after the IPO, which was known or should have been known by the company's executives [3]. Group 2: Financial Performance and Stock Price - Following the IPO, Klarna reported a net loss of $95 million as of November 18, 2025, and increased its provisions for loan losses to $235 million, exceeding analyst expectations [4]. - The provisions for loan losses represented 0.72% of gross merchandise volume, an increase from 0.44% the previous year [4]. - By the time the class action lawsuit commenced, Klarna's stock price had dropped to $31.31 per share, significantly below the IPO price of $40 [4]. Group 3: Legal Representation and Firm Background - Robbins Geller Rudman & Dowd LLP is representing investors in this class action lawsuit and is recognized as a leading law firm in securities fraud litigation [6]. - The firm has secured over $2.5 billion for investors in securities-related class action cases in 2024, highlighting its significant role in investor protection [6].